Summit Therapeutics (SMMT) Interest Expenses (2024)

Summit Therapeutics (SMMT) reported Interest Expenses of $9000.0 for Q4 2024, down 99.63% quarter-over-quarter from $2.5 million in Q3 2024.

Summit Therapeutics (SMMT) Interest Expenses (2024) Analysis & Trends

Summit Therapeutics has reported Interest Expenses for 1 years, with the latest figure at $9000.0 in Q4 2024.

For the quarter ending Q4 2024, Interest Expenses changed N/A year-over-year to $9000.0; the trailing twelve-month figure through Sep 2025 stood at $9000.0 (down 99.9% YoY), and the FY2024 full-year result was $8.7 million, down 47.23% from the prior year.
Interest Expenses for Q4 2024 stood at $9000.0, down from $2.5 million in the prior quarter.
The five-year high for Interest Expenses was $3.1 million in Q1 2024, with the low at $9000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Expense (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	-5.50 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	61,000.00
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-332,000.00
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-2,753.00
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	-
9	Abivax	91.71 Bn	91.71 Bn	-	-5.58 Mn
10	Summit Therapeutics	10.09 Bn	9.99 Bn	-	-

Download Data